|
|
 Previous Article | Table of Contents | Next Article 
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute
myelocytic leukemia: a CALGB study
J Yates, O Glidewell, P Wiernik, MR Cooper, D Steinberg, H Dosik, R Levy, C Hoagland, P Henry, A Gottlieb, C Cornell, J Berenberg, JL Hutchison, P Raich, N Nissen, RR Ellison, R Frelick, GW James, G Falkson, RT Silver, F Haurani, M Green, E Henderson, L Leone and JF Holland
A randomized comparison of the relative efficacy and toxicity of
daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m,
given on the first 3 days of a 7-day continuous infusion of cytosine
arabinoside (ara-C) at 100 mg/sq m/day, shows the outcome to be dependent
on anthracycline, dose, and patient age. DNR 45 is significantly better
than DNR 30 or ADM 30 for inducing complete remissions (CR) in patients
younger than 60 yr, (72%, 59%, 58% CRs, respectively). DNR 30 is better
than DNR 45 or ADM 30 for inducing CR in patients older than 60 yr (47%,
31%, 35%, respectively). There was a corresponding shift in the induction
mortality for the age, dose, and anthracycline groups. Adriamycin was
significantly more toxic to the gastrointestinal tract than daunorubicin.
The duration of complete remission, with cyclic courses of maintenance
therapy, was independent of the patient's age, the dose, or choice of
anthracycline used in induction, and of whether the maintenance courses
were given every 4 wk or every 8 wk.
Volume 60,
Issue 2,
pp. 454-462,
08/01/1982
Copyright © 1982 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J. Cornelissen, W. van Putten, and B. Lowenberg
Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia
Blood,
December 15, 2007;
110(13):
4619 - 4620.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia, G. Fillet, U. Jehn, W. Feremans, G. Meloni, M. Vignetti, et al.
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study
Haematologica,
March 1, 2007;
92(3):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Larson, R. M. Stone, R. J. Mayer, and C. A. Schiffer
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3556s - 3563s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. G. Gilliland, and J. M. Rowe
Drug therapy for acute myeloid leukemia
Blood,
August 15, 2005;
106(4):
1154 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Amadori, S. Suciu, U. Jehn, R. Stasi, X. Thomas, J.-P. Marie, P. Muus, F. Lefrere, Z. Berneman, G. Fillet, et al.
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
Blood,
July 1, 2005;
106(1):
27 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. F. Bradstock, J. P. Matthews, R. M. Lowenthal, H. Baxter, J. Catalano, T. Brighton, D. Gill, P. Eliadis, D. Joshua, P. Cannell, et al.
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine
Blood,
January 15, 2005;
105(2):
481 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe, D. Neuberg, W. Friedenberg, J. M. Bennett, E. Paietta, A. Z. Makary, J. L. Liesveld, C. N. Abboud, G. Dewald, F. A. Hayes, et al.
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
Blood,
January 15, 2004;
103(2):
479 - 485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Suciu, F. Mandelli, T. de Witte, R. Zittoun, E. Gallo, B. Labar, G. De Rosa, A. Belhabri, R. Giustolisi, R. Delarue, et al.
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Blood,
August 15, 2003;
102(4):
1232 - 1240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al.
Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
J. Clin. Oncol.,
February 15, 2003;
21(4):
615 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Davies, L. L. Robison, J. D. Buckley, T. Tjoa, W. G. Woods, G. A. Radloff, J. A. Ross, and J. P. Perentesis
Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
J. Clin. Oncol.,
March 1, 2001;
19(5):
1279 - 1287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, W. Kern, C. Schoch, C. Fonatsch, A. Heinecke, B. Wormann, and T. Buchner
Management of Acute Myeloid Leukemia in Elderly Patients
J. Clin. Oncol.,
November 1, 1999;
17(11):
3569 - 3576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Schneider
Response and remission criteria for clinical trials in lupus-- what can we learn from other diseases?
Lupus,
October 1, 1999;
8(8):
627 - 631.
[PDF]
|
|
|
|
|
|
|
J. M. Rowe and M. S. Tallman
Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?
Blood,
September 15, 1997;
90(6):
2121 - 2126.
[Full Text]
[PDF]
|
|
|
|
|
